December 21, 2017 / 11:35 AM / 6 months ago

BRIEF-Histogenics And Medinet Enter Licensing Agreement For Commercialization Of NeoCart In Japan

Dec 21 (Reuters) - Medinet Co Ltd:

* HISTOGENICS CORPORATION AND MEDINET CO., LTD ENTER INTO LICENSING AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NEOCART FOR THE JAPANESE MARKET

* HISTOGENICS - TRANSACTION TERMS INCLUDE A $10 MILLION UP-FRONT PAYMENT WITH A POTENTIAL OF $87 MILLION IN TOTAL MILESTONES, AND TIERED ROYALTIES ON SALES

* HISTOGENICS - PLANS TO INITIATE PHASE 3 CLINICAL TRIAL IN JAPAN IN SECOND HALF OF 2018 WITH POTENTIAL COMMERCIALIZATION IN JAPAN IN 2021 FOR NEOCART Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below